GlaxoSmithKline 2009.

Trial name or title	Efficacy and safety study of eltrombopag in pediatric patients with thrombocytopenia from chronic ITP (PETIT)
Methods	Phase II, multi‐center, 3‐part, staggered cohort, open‐label and double‐blind, randomized, placebo‐controlled study
Participants	Chronic ITP, a history of ITP for at least 6 months, PLT ≤ 30 × 109/l, one or more prior treatments for ITP, the dose of maintenance immunosuppressive regimens, primarily glucocorticoids must have been stable for at least 1 month, between 1 year and < 18 years of age
Interventions	Eltrombopag versus placebo
Outcomes	Primary outcome measure: overall platelet response Secondary outcome measures: incidence of adverse events, incidence of bleeding, incidence of requiring rescue therapy
Starting date	September 2009
Contact information	ClinicalTrials.gov identifier: NCT00908037
Notes	Study supported by GlaxoSmithKline

ITP: idiopathic thrombocytopenic purpura 
 PLT: platelet count